Brickell Biotech Inc

Change company Symbol lookup

Select an option...

BBI Brickell Biotech Inc

VTOL Bristow Group Inc

VTRS Viatris Inc

MSFT Microsoft Corp

NTB Bank of N T Butterfield & Son Ltd

CHN China Fund, Inc.

IGR CBRE Global Real Estate Income Fund

SURRY Sun Art Retail Group Ltd

VPV Invesco Pennsylvania Value Municipal Income Trust

HLBZ Helbiz Inc

Go

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company engaged in developing prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases. The Company’s pipeline combines several development-stage candidates and a cutting-edge platform with autoimmune and inflammatory disorders program for the treatment of primary axillary hyperhidrosis. Its products include Cialis, Taltz, Gemzar, Prozac, Cymbalta and Juvederm. Its lead development-stage program, BBI-02, is a Phase I ready, highly selective, and orally bioavailable DYRK1A inhibitor that has demonstrated in various preclinical models, including atopic dermatitis and rheumatoid arthritis. BBI-10, the Company’s lead early-stage STING inhibitor candidate, is a novel, potent, and orally available covalent STING inhibitor that specifically targets the palmitoylation site of STING, which allows to inhibit both wild-type STING and gain-of-function mutants.